OncoBone Therapeutics is pleased to announce the appointment of Dr. Michael Thormann as Vice President of Drug Discovery, effective August 19, 2025. Dr. Thormann brings more than two decades of leadership in medicinal chemistry and drug discovery, with a proven track record in advancing small molecules from concept to clinic.
OncoBone Therapeutics develops innovative therapies for cancer bone metastases up to IND-ready stage and partners with leading companies for clinical development. In parallel, the company is building its own internal therapeutic pipeline. As VP Drug Discovery, Dr. Thormann will lead the development of proprietary programs, including the small-molecule inhibitor OTX-001, the antibody-drug conjugate OTX-002, and the radiopharmaceutical OTX-003.
“We are delighted to welcome Michael to join our Team,” said Dr. Jussi Halleen, CEO of OncoBone Therapeutics. “His expertise in medicinal chemistry and drug discovery will be instrumental as we advance our pipeline and strengthen our position as a leader in therapies for cancer bone metastases.”
“I am excited to join OncoBone Therapeutics and contribute to its mission of improving outcomes for patients with bone metastases,” said Dr. Thormann. “The company has built a strong foundation, and I look forward to advancing our promising pipeline to deliver meaningful new treatment options for this significant unmet medical need.”